John Martin

Company: UCL, Yale University

Job title: Professor of Cardiovascular Medicine, Adjunct Professor of Internal Medicine

Seminars:

The Future of Small Molecule In Vivo Activated Cell Therapy: Modulation of Tregs in the Body 12:00 pm

AZD1656 is a specific activator of glucokinase; but not hexokinase (the latter is used by T effector lymphocytes for migration) A randomised blinded placebo-controlled trial of this drug in diabetic patients with Covid 19 significantly decreased death and time in hospital in the treated group. This trial was undertaken by the speaker and his team.…Read more

day: Day Two AM Cell-Based Approaches

Why has Cell Therapy Failed? 2:00 pm

The results of phase III trials in cell therapy have been disappointing The reason is because the expensive ex vivo manipulation or engineering of cells out of the body diminishes in vivo function. This applies to Treg therapy Tregs produce energy via glucokinase, activation of which increases migration of Tregs to sites of inflammation in…Read more

day: Day One PM Cell-Based Approaches